

**PROPOSED REGULATION OF THE
STATE BOARD OF PHARMACY**

LCB FILE NO. R144-18I

**The following document is the initial draft regulation proposed
by the agency submitted on 06/14/2018**

PROPOSED REGULATION OF THE NEVADA STATE BOARD OF PHARMACY

Workshop

June 7th, 2018

EXPLANATION – Matter in *italics* is new; matter in brackets [omitted material] is material to be omitted.

AUTHORITY: NRS 639.070(1)(d).

A REGULATION relating to the prescribing of controlled substances for the treatment of pain in conformance with Assembly Bill 474 (2017)

Section 1. Chapter 639 of NAC is hereby amended by adding thereto the provisions set forth in the section below.

Sec. 2. NAC 639 shall be amended to read as follows:

- 1. For the purpose of sections 53 and 54 of AB 474 (2017), an “informed written consent” can address a class of medication listed in schedule II, III, and IV for the treatment of pain, if when prescribing an initial prescription, the practitioner informs the patient that the medication is in the class. The practitioner must counsel the patient about the informed written consent and allow the patient to ask questions.*
- 2. For the purpose of section 55 of AB 474 (2017), an “assessment of the patient’s risk for abuse, dependency and addiction” can be completed either verbally or in written form and must contain at least one question regarding depression.*
- 3. For the purpose of sections 56 of AB 474 (2017), a “prescription medication agreement” can address a class of medication listed in schedule II, III, and IV for the treatment of pain, if when prescribing an initial prescription, the practitioner informs the patient that the medication is in the class and allows the patient to ask questions.*